According to GlobalData’s medical device pipeline database, 17 BRAF Other Tests devices are in various stages of development globally. GlobalData’s report BRAF Other Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, six are in active development, while the remaining 11 are in an inactive stage of development. There are three products in the early stages of development, and the remaining three are in the late stages of development.
Other BRAF tests covered in this model include In Situ Hybridization (ISH) and Mass Array. One unit refers to one test. ISH involves the denaturation of DNA or RNA to form single-stranded molecules, which naturally re-anneal to labelled probes made up of complementary nucleic acid sequences. Probes are designed to detect the presence or absence of specific genes or mutations and can be labelled in a variety of manners. Fluorescence in situ hybridization (FISH) either uses probes that are directly labelled with fluorophores, antigens or biotin. These are then subsequently bound by fluorescently tagged secondary compounds such as antibodies or streptavidin. FISH samples are typically viewed via fluorescence microscopy. Mass Array is a non-fluorescent detection platform that uses MALDI-TOF mass spectrometry to measure PCR-derived amplicons. This system has multiplex capabilities and can be used to for genotyping, mutation detection, and methylation analysis. Genes capable of being analyzed by Mass Array for oncology purposes include, but are not limited to, KRAS, EGFR, BRAF, NRAS, and PIK3CA.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed BRAF Other Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of BRAF Other Tests devices. Overall, most of these BRAF Other Tests pipeline devices are being developed by private entities.
Key players involved in the active development of BRAF Other Tests include Abbott Diagnostics, Amoy Diagnostics, Exosomics, GenomicTree, Memorial Sloan Kettering Cancer Center, MolecularMD, QuantuMDx Group, Syamala Srinivasa Life Sciences Pvt., University of Colorado and All India Institute of Medical Sciences.
For a complete picture of the developmental pipeline for BRAF Other Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
